Hypolipidemic  and Anti‐Obesity Effect of Anserine on Mice Orally Administered with High‐Fat Diet via Regulating SREBP‐1, NLRP3, and UCP‐1

This study describes that anserine can activate brown fat and increase the content of PGC1- α and UCP-1 proteins for anti-obesity action. Its mechanism of hypolipidemic and anti-obesity action may be to activate brown fat by inhibiting the NLRP3/NF-κB pathway protein secreting IL-1β. Thus, anserine may be a potential dietary supplement for decreasing blood fat and preventing obesity. AbstractTo investigate the efficacy of anserine on antiobesity, C57BL/6 mice are orally administered with a high-fat diet (HFD) and different doses of anserine (60, 120, and 240  mg/kg/day) for 16 weeks. Body weight, lipid, and epididymal fat content in mice are measured, and their liver damage is observed. The results display that the body weight, epididymal fat content, and low-density lipoprotein cholesterol (LDL-C) content in anserine groups are decreased by 4.36–18. 71%, 7.57–35.12%, and 24.32–44.40%, respectively. To further investigate the antiobesity mechanism of anserine, the expression of SREBP-1, NLRP3, NF-κB p65 (p65), and p-NF-κB p65 (p-p65) proteins in the liver and peroxisome proliferator-activated receptor gamma coactivator 1α (PGC1-α) and UC P-1 proteins in brown adipose tissue (BAT) is analyzed by Western blot. Results show that anserine can significantly decrease the expression of the NLRP3, p65, p-p65, and the SREBP-1 proteins and increase the expression of the PGC1-α and UCP-1 proteins. This study demonstrates that anserine lowered blood lipids and prevented ob...
Source: Molecular Nutrition and Food Research - Category: Food Science Authors: Tags: Research Article Source Type: research